David Carberry - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 16 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2022, 18:00:27 UTC
Prior SEC filing: 29 Aug 2022
Source filing: View source filing
Reporting owner signature: By: /s/ Richard Cunningham as attorney-in-fact for David Carberry

Key filing fact

David Carberry filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.

Key facts

This page summarizes David Carberry's Form 4 filing for TYME TECHNOLOGIES, INC..
8 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 16 Sep 2022, 18:00.

Change

Previous filing in this sequence was filed on 29 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TYME transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -100,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $2.95
Footnotes: F2

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -75,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $2.90
Footnotes: F3

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -50,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.33
Footnotes: F4

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -50,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.18
Footnotes: F5

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -65,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $1.22
Footnotes: F6

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -88,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,000
Exercise price: $1.10
Footnotes: F7

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -88,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,000
Exercise price: $1.10
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David Carberry is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,382 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.

Footnote F2

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.

Footnote F3

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.

Footnote F4

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.

Footnote F5

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.

Footnote F6

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.

Footnote F7

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.

Footnote F8

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.